Pharmaceutical co-crystals have acquired vast improvement in recent years due to its ability to change physicochemical properties of drugs. Pharmaceutical co-crystal consists of active pharmaceutical ingredient (API) and coformers. Co-crystals can be utilized to improve imperative physicochemical attributes of a medication, including solvency, disintegration, bioavailability and solidness of API while keeping up its therapeutic activity. Expanded commercialization of cocrystals has thus required extra research on techniques to make cocrystals, with specific highlight put on rising innovations that can be produced naturally attractive and efficient choices. In this review, well-organized and ordered overview of pharmaceutical cocrystal is provided, focusing on the solids forms of API, design strategy, its method of preparation, physicochemical properties, mechanism of enhancing solubility and its characterization technique. An overview of applications and marketed drug products of cocrystals is also described.

Keywords: Pharmaceutical co-crystals, physicochemical properties, cocrystallization, solubility, stability.

[1]. Sohrab M , Mahapatra S.P: Pharmaceutical Co-crystal. A New Paradigm for Enhancing the Physicochemical Properties of Active Pharmaceutical Ingredient. International journal of pharmacy and life sciences. 2015;6(3):4324-33.
[2]. Aakeröy CB, Salmon DJ.Building co-crystals with molecular sense and supramolecular sensibility. CrystEngComm. 2005;7:439-448.
[3]. Shan N, Zaworotko MJ. The role of cocrystals in pharmaceutical science. Drug discovery today. 2008;13(9-10):440-6.
[4]. Ter Horst JH, Deij MA, Cains PW. Discovering new co-crystals. Crystal Growth and Design. 2009;9(3):1531-7.
[5]. Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. Crystal growth and design. 2009;9(6):2950-67.

Urolithiasis is a complex process results from a succession of several physiochemical events including super saturation, nucleation, growth, aggregation and retention, within the kidneys. Traces of impurities cause marked modification in the growth and habit of both soluble and insoluble metal salts. It has been reported that strong absorption occurs on certain crystal faces only, and their rate of growth is markedly reduced, this may be due to formation of complexes with the additives. These complexing agents when complexed through polar groups are especially effective. This has further demonstrated that such absorption is much more active in solutions of the highly soluble metal salts than on the sols of less soluble metal salts of complexing cation...........

[1]. Moe OW. Kidney stones: pathophysiology and medical management. Lancet. 2006;367:333–344.

[2]. Tiselius HG. Epidemiology and medical management of stone disease. BJU Int. 2003;91:758–767.

[3]. Devuyst O, Pirson Y. Genetics of hypercalciuric stone forming diseases. Kidney Int. 2007;72:1065–1072.

[4]. Knoll T. Stone disease. Eur Urol Suppl. 2007;6:717–722. [Google Scholar]

[5]. Worcester EM, Coe FL. Nephrolithiasis. Prim Care. 2008;35:369–391. [Europe PMC free article

[6]. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005;293:455–462.

Nanocarriers present a great approach in drug delivery. Nanostructured lipid carriers (NLCs) are a recent approach for the delivery of poorly soluble drugs with low oral bioavailability. Nanostructured Lipid Carriers (NLCs) are mixture of solid lipids along with spatially incompatible liquid lipids. It remains solid at room temperature. It also overcomes the disadvantages of various lipid particulate carriers. The present review gives insights on the definitions and characterization of NLC as colloidal carriers including the production techniques.

Keywords: Nanotechnology, targeted drug delivery, nanocarrier, NLCs.

[1]. Mehnert W, Mader K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev., 2001, 47; 165-196.
[2]. Carmona-Ribeiro AM. Biomimetic nanoparticles: Preparation, characterization and biomedical applications. Int J Nanomed., 2010, 5; 249-259.
[3]. Mishra B, Patel BB, Tiwari S. Colloidal nanocarriers: A review on formulation technology, types and applications toward targeted drug delivery. Nanomedic., 2010, 6; 9-24.
[4]. Mujoriya R, Bodla RB, Dhamande K, Singh D, Patle L. Niosomal drug delivery system: The magic bullet. J Appl Pharm Sci., 2011, 01(09); 20-23.
[5]. Mehnert W, Mader K, Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev., 2001, 47(2-3); 96-165.

Cancer is major health problem in both developed and developing countries. Cancer after cardiovascular disease is the second leading cause of death. Cancer is the abnormal growth of cells in our bodies that can lead to death. Because of high death rate associated with cancer and because of serious side effects of chemotherapy and radiation therapy, many cancer patients seek alternative complementary methods of treatment. Plants have been used for treating diseases since time immemorial. More than 50% of modern drugs in clinical use are of natural products. In the present review, an attempt has been made to study the plants that have been used in the treatment of cancer.

Keywords: Cancer, Herbal, Leukemias

[1]. WHO calls for prevention of cancer through healthy workplaces? (Press release). World Health Organization. 27 April 2007. Retrieved 13 October2007.
[2]. Anilakumar K.R, Nagaraj N.S, Santhanam K. Effect of coriander seeds on hexachlorocyclo- hexane induced lipid peroxidation in rat liver. Nutr Res. 2001;21:1455–62.
[3]. Aruna K, Sivaramakrishnan V.M. Plant products as protective agents against cancer. Indian J Exp Biol. 1990;28:1008–11.
[4]. Aydin S, Basaran A.A, Basaran N. The effects of thyme volatiles on the induction of DNA damage by the heterocyclic amine IQ and mitomycinC.Mutat Res. 2005; 581:43–53.
[5]. BoehmK, Borrelli F, Ernst E, Habacher G, Hung SK, Milazzo S. Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst Rev 2009 Jul (3):-CD005004.

Background: Benzimidazoles are a group of hetrocyclic compounds containing fused benzene ring with an imidazole ring. It has been shown benzimidazolesretain important biological activity including antioxidant, analgesic and anti-inflammatory activity. In order to find analogues with improved activity, 13 benzimidazole derivatives which previously synthesized by our group were biologically investigated. Materials and Methods:This study is a pilot attempt to explore the antioxidant, analgesic and anti-inflammatory activity of the 13 compounds. The in vitroantioxidant potential was investigated using DPPH free radical scavenging assay. Two models of pain assessment i.e. thermally induced pain by hot plate and chemically induced pain by acetic acid were used to evaluate the analgesic activity of the compounds under test. However, formalin induced pain and inflammation in mouse paw was employed as a model to assess the anti-inflammatory activity.........

Keywords: Benzimidazole, Schiff base, Antioxidant, Analgesic, Anti-inflammatory.

[1]. Salahuddin, Shaharyar M, Mazumder A. Benzimidazoles: A biologically active compounds. Arab. J. Chem. 2017;10(1):S157-S173.
[2]. Kumar A, Banerjee S, Roy P, et al. Solvent-free synthesis and anticancer activity evaluation of benzimidazole and perimidine derivatives. Mol. Divers. 2018;22(1):113-127.
[3]. Cichero E, TonelliM, NovelliF,et al. Benzimidazole-based derivatives as privileged scaffold developed for the treatment of the RSV infection: A computational study exploring the potency and cytotoxicity profiles. J. Enzyme Inhib. Med. Chem. 2017;32(1):375-402.
[4]. Srivastava R, Gupta SK, Naaz F, Singh A, Singh VK, Verma R, Singh N, Singh RK. Synthesis, antibacterial activity, synergistic effect, cytotoxicity, docking and molecular dynamics of benzimidazole analogues. ComputBiol Chem. 2018;76:1-16.
[5]. Cindrić M, Perić M, Kralj M, Martin-Kleiner I, David-Cordonnier MH, Paljetak HČ, Matijašić M, Verbanac D, Karminski-Zamola G, Hranjec M. Antibacterial and antiproliferative activity of novel 2-benzimidazolyl- and 2-benzothiazolyl-substituted benzo[b]thieno-2-carboxamides. Mol. Divers. 2018;22(3):637-646.